OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 02, 2016 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 1:20 p.m. GMT (8:20 a.m. ET).
A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the TSPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company’s third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
[email protected]
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
[email protected]
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
[email protected]


China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 



